Eli Lilly And Stock Price To Sales

LLY Stock

USD 842.57 5.56 0.66%

Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	15.38	16.15

Price To Sales Ratio is likely to rise to 16.15 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eli Lilly and Company Price To Sales Analysis

Eli Lilly's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Eli Lilly Price To Sales

16.69 X

Most of Eli Lilly's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Eli Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Eli Lilly is extremely important. It helps to project a fair market value of Eli Stock properly, considering its historical fundamentals such as Price To Sales. Since Eli Lilly's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eli Lilly's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eli Lilly's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Debt	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Good Will	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.16	0.06	0.08	0.95	0.97	0.02	0.65	0.84	0.98	-0.33	-0.73	-0.73	0.92	0.54	0.82	0.65	0.86	-0.47	0.63	0.78	-0.14	0.79	-0.44	0.66	-0.35
Total Stockholder Equity	0.16		-0.32	0.97	-0.01	-0.07	0.08	-0.14	0.11	0.11	0.69	0.47	0.47	-0.17	-0.07	0.35	0.01	-0.01	0.67	-0.44	-0.23	0.7	-0.01	0.17	0.31	0.16
Net Debt	0.06	-0.32		-0.32	0.29	0.17	0.78	0.57	-0.08	0.05	-0.32	-0.36	-0.36	0.06	0.37	0.28	0.44	0.2	-0.54	0.51	0.36	-0.24	0.19	-0.36	-0.19	-0.63
Retained Earnings	0.08	0.97	-0.32		-0.12	-0.14	0.13	-0.18	0.01	0.01	0.77	0.57	0.57	-0.26	-0.02	0.28	-0.03	-0.15	0.68	-0.5	-0.31	0.78	-0.11	0.31	0.15	0.28
Net Receivables	0.95	-0.01	0.29	-0.12		0.97	0.14	0.75	0.79	0.95	-0.51	-0.84	-0.84	0.92	0.51	0.81	0.69	0.91	-0.6	0.76	0.85	-0.29	0.81	-0.58	0.64	-0.53
Total Liab	0.97	-0.07	0.17	-0.14	0.97		0.03	0.71	0.81	0.96	-0.5	-0.85	-0.85	0.97	0.57	0.78	0.69	0.87	-0.65	0.77	0.87	-0.3	0.8	-0.51	0.6	-0.4
Total Current Assets	0.02	0.08	0.78	0.13	0.14	0.03		0.25	-0.2	-0.1	0.05	0.03	0.03	-0.16	0.29	0.35	0.21	-0.11	-0.19	0.23	0.16	0.13	0.06	0.15	-0.28	-0.2
Intangible Assets	0.65	-0.14	0.57	-0.18	0.75	0.71	0.25		0.36	0.67	-0.4	-0.74	-0.74	0.67	0.53	0.64	0.78	0.75	-0.72	0.75	0.71	-0.17	0.43	-0.71	0.25	-0.64
Short Term Debt	0.84	0.11	-0.08	0.01	0.79	0.81	-0.2	0.36		0.87	-0.26	-0.57	-0.57	0.79	0.29	0.56	0.52	0.79	-0.25	0.39	0.55	-0.12	0.92	-0.41	0.78	-0.42
Accounts Payable	0.98	0.11	0.05	0.01	0.95	0.96	-0.1	0.67	0.87		-0.38	-0.76	-0.76	0.94	0.48	0.76	0.67	0.92	-0.47	0.62	0.76	-0.19	0.82	-0.57	0.72	-0.45
Short Term Investments	-0.33	0.69	-0.32	0.77	-0.51	-0.5	0.05	-0.4	-0.26	-0.38		0.78	0.78	-0.59	-0.26	-0.2	-0.27	-0.42	0.75	-0.75	-0.68	0.88	-0.29	0.46	-0.2	0.27
Capital Stock	-0.73	0.47	-0.36	0.57	-0.84	-0.85	0.03	-0.74	-0.57	-0.76	0.78		1.0	-0.88	-0.49	-0.5	-0.58	-0.81	0.85	-0.86	-0.85	0.66	-0.61	0.64	-0.36	0.52
Common Stock	-0.73	0.47	-0.36	0.57	-0.84	-0.85	0.03	-0.74	-0.57	-0.76	0.78	1.0		-0.88	-0.49	-0.5	-0.58	-0.81	0.85	-0.86	-0.85	0.66	-0.61	0.64	-0.36	0.52
Long Term Debt	0.92	-0.17	0.06	-0.26	0.92	0.97	-0.16	0.67	0.79	0.94	-0.59	-0.88	-0.88		0.52	0.68	0.65	0.87	-0.68	0.78	0.86	-0.41	0.75	-0.54	0.62	-0.35
Treasury Stock	0.54	-0.07	0.37	-0.02	0.51	0.57	0.29	0.53	0.29	0.48	-0.26	-0.49	-0.49	0.52		0.56	0.62	0.42	-0.54	0.57	0.59	-0.2	0.39	-0.17	0.14	-0.18
Property Plant Equipment	0.82	0.35	0.28	0.28	0.81	0.78	0.35	0.64	0.56	0.76	-0.2	-0.5	-0.5	0.68	0.56		0.74	0.68	-0.4	0.66	0.8	0.0	0.59	-0.4	0.6	-0.29
Good Will	0.65	0.01	0.44	-0.03	0.69	0.69	0.21	0.78	0.52	0.67	-0.27	-0.58	-0.58	0.65	0.62	0.74		0.7	-0.62	0.74	0.75	-0.15	0.64	-0.55	0.52	-0.5
Current Deferred Revenue	0.86	-0.01	0.2	-0.15	0.91	0.87	-0.11	0.75	0.79	0.92	-0.42	-0.81	-0.81	0.87	0.42	0.68	0.7		-0.51	0.66	0.73	-0.24	0.77	-0.75	0.69	-0.67
Net Tangible Assets	-0.47	0.67	-0.54	0.68	-0.6	-0.65	-0.19	-0.72	-0.25	-0.47	0.75	0.85	0.85	-0.68	-0.54	-0.4	-0.62	-0.51		-0.92	-0.82	0.66	-0.39	0.48	-0.06	0.37
Long Term Debt Total	0.63	-0.44	0.51	-0.5	0.76	0.77	0.23	0.75	0.39	0.62	-0.75	-0.86	-0.86	0.78	0.57	0.66	0.74	0.66	-0.92		0.95	-0.59	0.52	-0.54	0.36	-0.38
Capital Surpluse	0.78	-0.23	0.36	-0.31	0.85	0.87	0.16	0.71	0.55	0.76	-0.68	-0.85	-0.85	0.86	0.59	0.8	0.75	0.73	-0.82	0.95		-0.54	0.61	-0.54	0.51	-0.33
Long Term Investments	-0.14	0.7	-0.24	0.78	-0.29	-0.3	0.13	-0.17	-0.12	-0.19	0.88	0.66	0.66	-0.41	-0.2	0.0	-0.15	-0.24	0.66	-0.59	-0.54		-0.18	0.31	-0.04	0.16
Short Long Term Debt	0.79	-0.01	0.19	-0.11	0.81	0.8	0.06	0.43	0.92	0.82	-0.29	-0.61	-0.61	0.75	0.39	0.59	0.64	0.77	-0.39	0.52	0.61	-0.18		-0.4	0.7	-0.55
Cash And Equivalents	-0.44	0.17	-0.36	0.31	-0.58	-0.51	0.15	-0.71	-0.41	-0.57	0.46	0.64	0.64	-0.54	-0.17	-0.4	-0.55	-0.75	0.48	-0.54	-0.54	0.31	-0.4		-0.47	0.79
Net Invested Capital	0.66	0.31	-0.19	0.15	0.64	0.6	-0.28	0.25	0.78	0.72	-0.2	-0.36	-0.36	0.62	0.14	0.6	0.52	0.69	-0.06	0.36	0.51	-0.04	0.7	-0.47		-0.28
Net Working Capital	-0.35	0.16	-0.63	0.28	-0.53	-0.4	-0.2	-0.64	-0.42	-0.45	0.27	0.52	0.52	-0.35	-0.18	-0.29	-0.5	-0.67	0.37	-0.38	-0.33	0.16	-0.55	0.79	-0.28

Click cells to compare fundamentals

Eli Price To Sales Historical Pattern

Today, most investors in Eli Lilly Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eli Lilly's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eli Lilly price to sales as a starting point in their analysis.

Eli Lilly Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Eli Lilly

Price To Sales Ratio Over Time

Eli Price To Sales Ratio

Price To Sales Ratio

16.15

At this time, Eli Lilly's Price To Sales Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Eli Lilly and has a Price To Sales of 16.6903 times. This is 22.01% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to sales for all United States stocks is 46.15% lower than that of the firm.

Eli Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.

Eli Lilly is currently under evaluation in price to sales category among its peers.

Eli Lilly ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.

Environmental

Governance

Social

Eli Fundamentals

	Return On Equity	0.84
	Return On Asset	0.15
	Profit Margin	0.24 %
	Operating Margin	0.43 %
	Current Valuation	768.97 B
	Shares Outstanding	898.17 M
	Shares Owned By Insiders	0.16 %
	Shares Owned By Institutions	83.53 %
	Number Of Shares Shorted	7.24 M
	Price To Earning	54.92 X
	Price To Book	52.05 X
	Price To Sales	16.69 X
	Revenue	45.04 B
	Gross Profit	36.62 B
	EBITDA	15.23 B
	Net Income	10.59 B
	Cash And Equivalents	2.07 B
	Cash Per Share	2.97 X
	Total Debt	33.64 B
	Debt To Equity	1.58 %
	Current Ratio	1.13 X
	Book Value Per Share	15.81 X
	Cash Flow From Operations	8.82 B
	Short Ratio	2.11 X
	Earnings Per Share	11.89 X
	Price To Earnings To Growth	1.21 X
	Target Price	1010.47
	Number Of Employees	47 K
	Beta	0.34
	Market Capitalization	751.78 B
	Total Asset	78.71 B
	Retained Earnings	13.54 B
	Working Capital	4.36 B
	Current Asset	12.57 B
	Current Liabilities	8.23 B
	Annual Yield	0.01 %
	Five Year Return	1.83 %
	Net Asset	78.71 B
	Last Dividend Paid	5.2

About Eli Lilly Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC